Standard Operating Procedure: Safety Reporting in Clinical Trials

Introduction

This Standard Operating Procedure (SOP) establishes the mandatory framework for the identification, documentation, and expedited reporting of Adverse Events (AEs) and Serious Adverse Events (SAEs) within clinical trials. Maintaining accurate safety data is a critical regulatory requirement (ICH-GCP E6 R2) to ensure participant protection, maintain trial integrity, and meet the reporting obligations mandated by Health Authorities (e.g., FDA, EMA) and Institutional Review Boards (IRBs/IECs). Adherence to this SOP is mandatory for all site personnel, including Principal Investigators (PIs), Clinical Research Coordinators (CRCs), and sub-investigators.

Phase 1: Identification and Initial Documentation

• AE Identification: Promptly identify any untoward medical occurrence in a participant, regardless of causal relationship to the investigational product (IP).
• Assessment of Severity: Determine severity (Mild, Moderate, Severe) based on protocol-defined criteria or standard medical judgment.
• Causality Assessment: The PI must provide an initial assessment of the relationship between the IP and the AE (e.g., Related, Unrelated, Possible, Probable).
• Documentation: Record the AE in the participant’s source documents (medical charts/notes) and the Case Report Form (CRF) immediately upon discovery or notification.

Phase 2: SAE Classification and Reporting

• SAE Screening: Determine if the AE meets the definition of "Serious" (Results in death, life-threatening, inpatient hospitalization/prolonged stay, disability/incapacity, or congenital anomaly).
• Expedited Notification: Notify the Sponsor/CRO within 24 hours of site awareness of any SAE, regardless of expectedness or causality.
• Initial Report Form: Complete the designated SAE Report Form with all available information at the time of the initial notification.
• Reporting to IRB/IEC: Notify the local IRB/IEC of the SAE in accordance with institutional timelines and local regulatory requirements.

Phase 3: Follow-Up and Reconciliation

• Continuous Monitoring: Maintain active follow-up of the SAE until resolution, stabilization, or the participant is lost to follow-up.
• Submission of Follow-up Reports: Submit updated SAE forms to the Sponsor as significant new information becomes available (e.g., lab results, autopsy reports, discharge summaries).
• Query Resolution: Address any queries generated by the Sponsor or Data Management team regarding discrepancies between the CRF and the SAE report within 48 hours.
• Reconciliation: Periodically perform a reconciliation check between the site’s AE/SAE logs and the Sponsor’s clinical database to ensure 100% data alignment.

Pro Tips & Pitfalls

• Pitfall - The "Missing Data" Trap: Avoid submitting incomplete SAE reports to "meet the 24-hour deadline." Send the initial report with the information you have, then use the Follow-up process to add missing details.
• Pro Tip - Source Verification: Ensure that the event is documented in the participant’s medical record before entering it into the electronic CRF. Discrepancies between source and CRF are the most common finding during regulatory audits.
• Pitfall - Under-reporting: Do not filter "minor" events. If it meets the protocol definition of an AE, report it. It is better to have an AE downgraded by the sponsor than to have an unreported event discovered during a monitor visit.
• Pro Tip - Investigator Oversight: Ensure the PI personally signs and dates the causality assessment for every SAE. Delegating this to the CRC is a major compliance violation.

Frequently Asked Questions

1. What happens if I receive a report of an SAE outside of business hours? The 24-hour reporting clock begins the moment the site (any staff member) becomes aware of the event. If the event occurs on a weekend, ensure the site’s "After-Hours Safety Reporting" procedure is followed, which typically involves emailing the dedicated safety hotline or calling the Sponsor’s medical monitor.

2. Does an Adverse Event need to be reported if the patient was not taking the study drug at the time? Yes. In clinical trials, the safety reporting period usually begins upon the signing of the Informed Consent Form. Any AE occurring after consent, even during a washout period or before the first dose, must be recorded and reported as per the protocol.

3. What is the difference between "Expected" and "Unexpected" safety events? An "Expected" event is one that is listed in the current Investigator’s Brochure (IB) or Protocol. An "Unexpected" event is one that is not listed or occurs with a greater severity/frequency than previously documented. Unexpected SAEs often require additional, immediate notification to regulatory authorities (e.g., SUSAR reports).